MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB

PURPOSE: To determine if BRAF and/or MEK inhibitor-induced GPNMB expression renders melanomas sensitive to CDX-011, an antibody-drug conjugate targeting GPNMB. EXPERIMENTAL DESIGN: The TCGA melanoma dataset was interrogated for a panel of MITF-regulated melanosomal differentiation antigens, includin...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Rose, April A. N., Annis, Matthew G., Frederick, Dennie T., Biondini, Marco, Dong, Zhifeng, Kwong, Lawrence, Chin, Lynda, Keler, Tibor, Hawthorne, Thomas, Watson, Ian R., Flaherty, Keith T., Siegel, Peter M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168941/
https://ncbi.nlm.nih.gov/pubmed/27515299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1192
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi